Spudich S - Search Results

1

Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.

Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JL, Chalermchai T, Krebs SJ, Robb ML, Hellmuth J, Gisslén M, Zetterberg H, Spudich S; RV254SEARCH 010, RV304SEARCH 013, and SEARCH 011 Study Teams. Peluso MJ, et al. Among authors: spudich s. AIDS. 2017 Jan 14;31(2):247-252. doi: 10.1097/QAD.0000000000001314. AIDS. 2017. PMID: 27819802 Free PMC article.

2

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Spudich SS, et al. BMC Infect Dis. 2005 Nov 2;5:98. doi: 10.1186/1471-2334-5-98. BMC Infect Dis. 2005. PMID: 16266436 Free PMC article.

3

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.

Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Spudich S, et al. J Infect Dis. 2006 Dec 15;194(12):1686-96. doi: 10.1086/508750. Epub 2006 Nov 3. J Infect Dis. 2006. PMID: 17109340

4

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Yilmaz A, et al. Among authors: spudich s. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73. doi: 10.1097/QAI.0b013e31815ace97. J Acquir Immune Defic Syndr. 2008. PMID: 17971711 Free PMC article.

5

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.

Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Gisslen M, et al. Among authors: spudich s. J Neuroimmune Pharmacol. 2007 Mar;2(1):112-9. doi: 10.1007/s11481-006-9035-1. Epub 2006 Sep 12. J Neuroimmune Pharmacol. 2007. PMID: 18040834 Review.

6

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Edén A, et al. Among authors: spudich s. J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648. J Infect Dis. 2007. PMID: 18190258

7

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW. Sinclair E, et al. Among authors: spudich s. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):544-52. doi: 10.1097/QAI.0b013e318162754f. J Acquir Immune Defic Syndr. 2008. PMID: 18362693 Free PMC article.

8

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.

Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Yilmaz A, et al. Among authors: spudich s. PLoS One. 2009 Sep 1;4(9):e6877. doi: 10.1371/journal.pone.0006877. PLoS One. 2009. PMID: 19721718 Free PMC article.

9

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, Zetterberg H. Gisslén M, et al. Among authors: spudich s. BMC Neurol. 2009 Dec 22;9:63. doi: 10.1186/1471-2377-9-63. BMC Neurol. 2009. PMID: 20028512 Free PMC article.

10

Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation.

Probasco JC, Deeks SG, Lee E, Hoh R, Hunt PW, Liegler T, Price RW, Spudich SS. Probasco JC, et al. Among authors: spudich ss. AIDS. 2010 Apr 24;24(7):1001-5. doi: 10.1097/QAD.0b013e328331e15b. AIDS. 2010. PMID: 20299968

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters